Abstract:Background The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies against cancer. Due to the poor availability of benign tissues, if available, normal tissue adjacent to the tumor has been used as a benign surrogate when defining tumor-associated antigens. However, this comparison has proven to be insufficient and even resulted in lethal outcomes. In order to match the tumor immunopeptidome with an equivalent counterpart, we created the HLA Ligand Atlas, the first extensive collection of paired HLA-I and HLA-II immunopeptidomes from 227 benign human tissue samples. This dataset facilitates a balanced comparison between tumor and benign tissues on HLA ligand level. Methods Human tissue samples were obtained from 16 subjects at autopsy, five thymus samples and two ovary samples originating from living donors. HLA ligands were isolated via immunoaffinity purification and analyzed in over 1200 liquid chromatography mass spectrometry runs. Experimentally and computationally reproducible protocols were employed for data acquisition and processing. Results The initial release covers 51 HLA-I and 86 HLA-II allotypes presenting 90,428 HLA-I- and 142,625 HLA-II ligands. The HLA allotypes are representative for the world population. We observe that immunopeptidomes differ considerably between tissues and individuals on source protein and HLA-ligand level. Moreover, we discover 1407 HLA-I ligands from non-canonical genomic regions. Such peptides were previously described in tumors, peripheral blood mononuclear cells (PBMCs), healthy lung tissues and cell lines. In a case study in glioblastoma, we show that potential on-target off-tumor adverse events in immunotherapy can be avoided by comparing tumor immunopeptidomes to the provided multi-tissue reference. Conclusion Given that T-cell-based immunotherapies, such as CAR-T cells, affinity-enhanced T cell transfer, cancer vaccines and immune checkpoint inhibition, have significant side effects, the HLA Ligand Atlas is the first step toward defining tumor-associated targets with an improved safety profile. The resource provides insights into basic and applied immune-associated questions in the context of cancer immunotherapy, infection, transplantation, allergy and autoimmunity. It is publicly available and can be browsed in an easy-to-use web interface at https://hla-ligand-atlas.org .

Caatlas: an Immunopeptidome Atlas of Human Cancer.

TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.

MicroEpitope: an atlas of immune epitopes derived from cancer microbiomes

IEAtlas: an atlas of HLA-presented immune epitopes derived from non-coding regions

The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides

An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy

Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery

Antigen discovery for the development of cancer immunotherapy

Application of Mass Spectrometry-Based MHC Immunopeptidome Profiling in Neoantigen Identification for Tumor Immunotherapy

The SysteMHC Atlas v2.0, an updated resource for mass spectrometry-based immunopeptidomics

Identification of tumor antigens with immunopeptidomics

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

HMPA: a pioneering framework for the noncanonical peptidome from discovery to functional insights

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

Identification Of Mhc Peptides Using Mass Spectrometry For Neoantigen Discovery And Cancer Vaccine Development

A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources

CancerProteome: a resource to functionally decipher the proteome landscape in cancer

MHC Class II Restricted Neoantigen Peptides Predicted by Clonal Mutation Analysis in Lung Adenocarcinoma Patients: Implications on Prognostic Immunological Biomarker and Vaccine Design.

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

Shedding light on the hidden human proteome expands immunopeptidome in cancer

dbPepNeo: a manually curated database for human tumor neoantigen peptides